$GMAB News

Genmab (GMAB) Posts Perfect Technical and Setup Scores in Breakout Setup

Genmab's H1 Preview: Darzalex Beats The Sales Outlook

TD Cowen Upgrades Genmab to Buy, Raises Price Target to $43

Genmab’s TEPKINLY + R2 Wins EU Approval As First Bispecific Therapy For Relapsed Follicular Lymphoma Following Phase 3 Trial Success

HC Wainwright & Co. Maintains Buy on Genmab, Raises Price Target to $40

Genmab Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Objective, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $38 Price Target

Major Shareholder Announcement

Genmab Discloses Orbis Investment Management Holds 4.99% Voting Rights Stake Of The Company As Of June 12, 2026

Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

Reported Saturday, Genmab's Epcoritamab Monotherapy Achieves 67% ORR And 58% CR Rate While Combination With R-Mini-CHOP Delivers 93% ORR And 86% CR In Elderly Newly Diagnosed DLBCL Patients

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Genmab Data From Pivotal Phase 3 EPCORE FL-1 Study Of Epcoritamab In Combination With Rituximab And Lenalidomide Demonstrates Consistent, Sustained Efficacy Benefits Throughout Clinically Relevant Subgroups

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

Genmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation Estimate

Morgan Stanley Maintains an “Equal Weight” Rating on Genmab A/S (GMAB)

Capital Increase in Genmab as a Result of Employee Warrant Exercise